Results 221 to 230 of about 6,029,052 (258)

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Early Clinical, Imaging, and Pathological Characteristics of SRPK3/TTN‐Digenic Myopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SRPK3/TTN‐digenic myopathy was recently established as a skeletal muscle myopathy caused by digenic inheritance. This study characterizes the early clinical presentation of SRPK3/TTN‐digenic myopathy in one previously reported and seven newly identified pediatric patients.
Rotem Orbach, Sandra Donkervoort, Carola Hedberg‐Oldfors, Giovanni Baranello, Dimah Saade, Precilla D'Souza, Ruchee Patel, Eva Michael, A. Reghan Foley, Diana Bharucha‐Goebel, S. Jin Haugland, Meghan McAnally, Omer Abdul Hamid, Katherine Chao, Ellen F. Macnamara, Alan H. Beggs, Anna Sarkozy, Juliane Mueller, Steven A. Moore, Richard S. Finkel, Cynthia J. Tifft, Francesco Muntoni, Anders Oldfors, Carsten G. Bönnemann   +23 more
wiley   +1 more source

Editorial: Advances in plant-derived pharmaceuticals: exploring secondary metabolites for therapeutic innovation. [PDF]

Front Plant Sci
Mopuri R, Tan CH.
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Computational Design of RNA Aptamers Targeting Oncogenic miR-10b Using T‑SELEX and Molecular Dynamics-Based Stability Metrics. [PDF]

ACS Omega
Mokgopa KP, Lobb KA, Tshiwawa T.
europepmc   +1 more source

Arthroscopic-Assisted Adjustable Progressive Compression Fixation for Distal Tibiofibular Syndesmosis Injury. [PDF]

Arthrosc Tech
Li K, Chen Y, Guo Q, Zhang B, Zhang H, Chen Q.   +5 more
europepmc   +1 more source

Plant Secondary Metabolites for the Control of Plant Diseases: Antiviral, Antifungal, and Antibacterial Activities and Their Biotechnological Applications. [PDF]

Life (Basel)
Basak E, Ulusal B, Bingol AB, Turker M, Ustundag CB, Yilmaz I.   +5 more
europepmc   +1 more source

Improving Interfacial Stability for All-Solid-State Secondary Batteries with Precursor-Based Gradient Doping

ACS Omega
Yong Jun Ji, Yong Joon Park
doaj   +1 more source